# MOUNTAINEER-03 (NCT05253651)

> A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05253651
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Colorectal Neoplasms
- Interventions: tucatinib; trastuzumab; bevacizumab; cetuximab; oxaliplatin; leucovorin; levoleucovorin; fluorouracil
- Enrollment: 400
- Primary outcome: Progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) by Blinded Independent Central Review (BICR)

## Commentary we found

- YouTube: 9
- Podcasts: 8
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=mountaineer-03-nct05253651

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05253651", "email": "<work email>"}; the inbox owner confirms by the emailed link.